ArticleBMC cancer2025
Dentate line invasion is a risk factor for locoregional recurrence and distant metastasis following abdominoperineal resection in rectal cancer: a single-centre retrospective cohort study based on 1854 cases.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundIn the context of surgical treatment for rectal cancer, the dentate line is acknowledged as a critical anatomical landmark. However, the prognostic implications of dentate line invasion (DLI) remain elusive and warrant further investigation. This study aims to evaluate and compare the outcomes of patients with rectal cancer who underwent abdominoperineal resection (APR), distinguishing between those with and without DLI. MATERIALS AND
methodsBetween January 2006 and December 2017, this study enrolled 1854 patients with rectal cancer who underwent APR. The cohort was divided into two groups, namely the DLI group (n = 340) and the non-DLI group (n = 1514). The primary endpoints were distant relapse-free survival (DRFS) and local recurrence-free survival (LRFS). Univariate and multivariate analyses were conducted to assess the impact of DLI on DRFS, LRFS, overall survival (OS), and disease-free survival (DFS).
resultsThe median follow-up duration for the patients was 92.9 months, with a 5-year OS rate of 92.0% for the entire cohort. Compared to the non-DLI group, patients in the DLI group showed significantly poorer outcomes, with 5-year DRFS at 57.4% vs. 73.9% (P < 0.001), DFS at 51.2% vs. 70.7% (P < 0.001), and LRFS at 71.7% vs. 88.5% (P = 0.018). OS was the only metric that showed no significant difference(89.0% vs. 92.6%, P = 0.064). Multivariate analysis demonstrated that DLI negatively impacted DRFS (hazard ratio HR 1.319, P = 0.029), LRFS (HR 2.059, P < 0.001), and DFS (HR 1.563, P < 0.001) as an independent prognostic factor. Furthermore, distant metastasis occurred more frequently in the DLI group (30.0% vs. 23.1%, P = 0.002), along with a higher rate of locoregional recurrence. (16.8% vs. 8.3%, P < 0.001).
conclusionsDLI correlates with a heightened likelihood of locoregional recurrence and distant metastasis among rectal cancer patients treated with APR. This association underscores the significance of DLI as a crucial prognostic factor that should be considered when developing clinical management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.